Silk Road Medical Inc (SILK) Stock
SILK is no longer traded. Silk Road Medical was acquired by Boston Scientific (BSX) on September 17, 2024.
Each SILK share was exchanged for $27.50 in cash. Prices on this page are historical; the last trade was September 16, 2024 at $27.49.
See Boston Scientific (BSX) stock →Silk Road Medical stock price history
SILK final trading statistics
- Final close
- $27.49
- Final trading day
- Sep 16, 2024
- Market cap at delisting
- $1.12B
- Shares outstanding
- 40.63M
- Final 52-week range
- $6.08 – $27.51
- Avg. volume (final 3 mo.)
- 2,061,400
- All-time high (split-adj.)
- $69.94 · Nov 2020
- All-time low (split-adj.)
- $6.29 · Oct 2023
- Return since IPO
- -24.0%
- Beta
- 1.54
- Book value / share
- $3.81
- Price / book
- 7.22
Silk Road Medical annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $177.13M | -$55.7M | -$1.44 |
| FY2022 | $138.64M | -$58.0M | -$1.54 |
| FY2021 | $101.47M | -$50.4M | -$1.44 |
| FY2020 | $75.23M | -$50.4M | -$1.44 |
| FY2019 | $63.35M | -$56.1M | -$21.07 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Silk Road Medical Inc
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation.
Silk Road Medical stock FAQ
What happened to Silk Road Medical stock?
Silk Road Medical was acquired by Boston Scientific (BSX) on September 17, 2024. Shareholders received $27.50 in cash for each share. SILK stock stopped trading on the Nasdaq, with a final close of $27.49 on September 16, 2024.
What did Silk Road Medical shareholders receive?
Each SILK share was converted into $27.50 in cash. The deal was valued at about $1.26 billion.
Is SILK stock still trading?
No. SILK was delisted from the Nasdaq on September 17, 2024 and no longer trades on a U.S. exchange.
What was the last price of SILK stock?
SILK closed at $27.49 on its final trading day, September 16, 2024, for a market value of about $1.12B.
What were Silk Road Medical's revenue and earnings in its last full fiscal year?
Silk Road Medical reported revenue of $177.13M and net income of -$55.7M in fiscal 2023, its last full year as a public company.
When did Silk Road Medical go public?
Silk Road Medical Inc stock began trading on April 4, 2019.